Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.170
-0.020 (-1.68%)
At close: Jan 9, 2026, 4:00 PM EST
1.240
+0.070 (5.98%)
After-hours: Jan 9, 2026, 7:51 PM EST
Allarity Therapeutics Employees
As of December 31, 2024, Allarity Therapeutics had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$2,187,286
Market Cap
20.32M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | 1 | 16.67% |
| Dec 31, 2023 | 6 | -3 | -33.33% |
| Dec 31, 2022 | 9 | -4 | -30.77% |
| Dec 31, 2021 | 13 | -1 | -7.14% |
| Dec 31, 2020 | 14 | -2 | -12.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALLR News
- 10 days ago - Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months - GlobeNewsWire
- 4 months ago - Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 - GlobeNewsWire
- 4 months ago - Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer - GlobeNewsWire
- 5 months ago - Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships - GlobeNewsWire
- 6 months ago - Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization - GlobeNewsWire
- 6 months ago - Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer - GlobeNewsWire